Acasti Pharma Inc. Class A - ADR Peer Comparison
$3.28
$-0.09
(-2.67%)
As on 21-Nov-2024 09:30EDT
Market cap
$34 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Edit
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
34 | 2,356 | 1,183 | 647 | 308 |
Revenue ($ Mln) |
-- | 10,853 | 225 | 182 | 928 |
Net Profit ($ Mln) |
-11.61 | -1,098.00 | 69.79 | 153.05 | -21.69 |
Net Margin (%) |
-- | -10.12 | 30.98 | 84.23 | -2.34 |
RoE (%) |
-19.69 | -- | 5.60 | 91.29 | -2.00 |
Price to Earnings |
-- | -- | 16.89 | 5.34 | -- |
Price-To-Book |
0.59 | 18.78 | 1.17 | 3.83 | 0.45 |
Cashflow ($ Mln)
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-12.33 | 1,597.00 | 18.84 | -64.85 | 54.91 |
|
Cash Flow from Investing Activities
|
-- | -454.00 | 175.15 | 22.95 | 17.76 |
|
Cash from Financing Activities
|
7.36 | -868.00 | -1.23 | 52.00 | -49.36 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-19.75 | -0.22 | 3.79 | -64.08 | -7.11 |
|
ROE (%)
|
-19.69 | 4.00 | 3.80 | -68.76 | -8.08 |
|
ROA (%)
|
-15.72 | -0.17 | 3.56 | -50.65 | -6.72 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -0.48 | 34.93 | -1,133.04 | -10.30 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.10 | 0.35 | -0.66 | 0.01 |
|
EBIT Growth (%)
|
-152.17 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
71.50 | 92.23 | 155.54 | 4.02 | 45.10 |
|
EPS Growth (%)
|
-- | 0.92 | 1.55 | 0.15 | 0.45 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -65.18 | 19.01 | -8.88 | -4.97 |
|
Price / Book Value
|
-- | -2.34 | 0.73 | 6.38 | 0.42 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
2.04 | 7.54 | 1.51 | -7.38 | -9.08 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -17.06 | 0.00 | 0.06 | 0.13 |
|
Short term debt to equity ratio
|
0.00 | -2.14 | 0.00 | 0.00 | 0.03 |
|
Current Ratio
|
6.01 | 0.86 | 18.84 | 8.15 | 5.10 |
|
Quick Ratio
|
6.01 | 0.62 | 18.17 | 5.95 | 3.67 |
|
Interest Coverage
|
-16.85 | 1.35 | -- | -509.36 | -12.72 |
Operating Efficiency Ratios
| Acasti Pharma Inc. Class A - ADR | Bausch Health Companies (BHC) | Cronos Group Inc. Common Share (CRON) | Arbutus Biopharma Corp (ABUS) | Sundial Growers - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 22.23 | 25.31 | 39.04 | 3.05 |
|
Asset Turnover
|
0.00 | 0.36 | 0.10 | 0.04 | 0.65 |
|
Receivable days
|
-- | 78.51 | 101.93 | 123.85 | 10.95 |
|
Inventory Days
|
-- | 206.06 | 125.77 | -470.06 | 69.44 |
|
Payable days
|
37,338.51 | 90.26 | 57.51 | 733.01 | 13.18 |
|
Cash Conversion Cycle
|
-- | 194.31 | 170.19 | -1,079.22 | 67.20 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
